Skip to main content
Notable Settlement
Healthcare
$350 Million

DaVita — Dialysis Referral Inducements

DaVita Pays $350 Million for Dialysis Referral Kickback Scheme

By Angie KellyLast updated: December 4, 2024

Source: U.S. Department of Justice

TL;DR: DaVita Pays $350 Million for Dialysis Referral Kickback Scheme This case resulted in a $350 Million resolution and demonstrates the impact of whistleblower protections in recovering funds from fraud.

Summary

DaVita Healthcare Partners, Inc. agreed to pay $350 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce patient referrals to its dialysis clinics. DOJ alleged that, between March 2005 and February 2014, DaVita targeted physicians with substantial renal-disease patient populations and offered lucrative joint venture opportunities involving ownership interests in dialysis clinics, coupled with additional arrangements (including medical director and non-compete agreements) intended to lock in referrals. DOJ reported the matter was brought as a qui tam case.

Our Take

Dialysis referral-inducement cases often hinge on deal design: who was selected, why they were selected, what economic upside they received, and how the relationship tracked referral volume. Insiders frequently have investor pitch materials, referral projections, deal emails, and compensation records that show whether the arrangement was built around business generation rather than legitimate services. If you've seen "partnership" discussions that quietly revolve around patient flow, the most useful step is mapping the timeline of offers, signatures, and subsequent referral changes.

Read the full article from the original source:

View Original Article

Opens in a new tab. Content from U.S. Department of Justice.

Notice

The summaries above are based on publicly available information released by the U.S. Department of Justice and are provided for informational purposes only. They do not constitute legal advice, investigative findings, or allegations by Disclosure Strategy. Our commentary reflects general, experience-based observations about how False Claims Act matters commonly arise and is not a statement about any party's liability.